Overview

Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Bausch Health Americas, Inc.
Treatments:
Brodalumab